Literature DB >> 9663176

Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population.

C Martínez1, J A Agúndez, M Olivera, A Llerena, R Ramirez, M Hernández, J Benítez.   

Abstract

OBJECTIVES AND STUDY
DESIGN: The genetic basis of two polymorphisms of drug- and carcinogen-metabolizing enzymes, NAT2 (arylamine N-acetyltransferase-2) and CYP2E1 (cytochrome P450 2E1), was studied in genomic deoxyribonucleic acid from 137 healthy, unrelated subjects from a mixed Nicaraguan population.
RESULTS: Six point mutations were identified at the coding region of the NAT2 gene, including the most common alleles NAT2*4 (41.6%), NAT2*5B (31.4%), and NAT2*6A (16.8%). The percentage of carriers of two defective genes was 49.6%. The Nicaraguan population studied was in Hardy-Weinberg's disequilibrium for the NAT2 genotype (p < 0.01) and the allele frequencies were significantly different from those of other populations, being intermediate between those of pure Central American Indians and Spanish persons. The frequency of CYP2E1 alleles mutated at the RsaI site (c2 allele; 16.5%) was intermediate between that of Spanish white and Asian subjects. About 5% of the subjects were homozygous for the c2 allele.
CONCLUSIONS: These findings indicate a high impact of genetic admixture of populations of Asian origin (Central American Indians) and white persons (Spaniards) on the genetic polymorphisms studied here and suggest that among mixed Hispanics a high heterogeneity of genotypes and phenotypes can be expected depending on the degree of genetic admixture of every subgroup. Therefore different subgroups of mixed Hispanic subjects can exhibit different results when treated with drugs that are inactivated through polymorphic enzymes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9663176     DOI: 10.1016/S0009-9236(98)90085-6

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Cervical cancer and CYP2E1 polymorphisms: implications for molecular epidemiology.

Authors:  Paula M Ferreira; Raquel Catarino; Deolinda Pereira; Ana Matos; Daniela Pinto; Ana Coelho; Carlos Lopes; Rui Medeiros
Journal:  Eur J Clin Pharmacol       Date:  2005-12-22       Impact factor: 2.953

Review 2.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

3.  Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.

Authors:  R Salazar-González; R Gómez; S Romano-Moreno; S Medellín-Garibay; A Núñez-Ruíz; M Magaña-Aquino; R C Milán-Segovia; D P Portales-Pérez
Journal:  Mol Biol Rep       Date:  2014-08-28       Impact factor: 2.316

4.  Maternal smoking, xenobiotic metabolizing enzyme gene variants, and gastroschisis risk.

Authors:  Mary M Jenkins; Jennita Reefhuis; Margaret L Gallagher; Jennifer G Mulle; Thomas J Hoffmann; Deborah A Koontz; Cynthia Sturchio; Sonja A Rasmussen; John S Witte; Patricia Richter; Margaret A Honein
Journal:  Am J Med Genet A       Date:  2014-03-25       Impact factor: 2.802

5.  Inferring haplotypes at the NAT2 locus: the computational approach.

Authors:  Audrey Sabbagh; Pierre Darlu
Journal:  BMC Genet       Date:  2005-06-02       Impact factor: 2.797

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.